Supplements · Diets · Metabolic & Cardiometabolic
exogenous ketones decreases postprandial glucose
In plain terms: Do ketone drinks lower blood sugar after a meal?
Strong support Supplements 💰 Industry COI noted🔬 Includes disconfirming
Part of: 🧪 exogenous ketones
RefutedContestedStrong support
consensus score 0.72
Yes, modestly and short-term, but they don't improve long-term blood-sugar control.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
13 support 1 contradict 1 tested null 1 mixed · 16 sources, 11 independent groups
What the evidence shows
Exogenous ketones acutely and modestly lower blood glucose (~0.5 mM; reduced postprandial AUC), including in type 2 diabetes - via BHB suppressing hepatic glucose output/lipolysis. Real but acute; no chronic glycemic-control (HbA1c) benefit shown.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Bharmal 2021 · J Nutr | RCT | supports | high | Ketone monoester acutely lowered plasma glucose during nutritional ketosis in prediabetes |
| Greaves G et al] # corrected 2026-08-17 from PubMed; was [(Little lab) 2021 · (RCT) | RCT | supports | moderate | RCT: prior ketone ester lowered glucose AUC during mixed-meal test |
| Walsh 2021 · J Clin Endocrinol Metab | RCT | supports | high | 14-day ketone monoester lowered fasting/postprandial glucose + vascular function in obesity (crossover) |
| Falkenhain K. 2025 · study_type: observational | observational | supports | low | Narrative review synthesizing historical and contemporary human/animal studies on exogenous ketone (BHB) supplementation; concludes exogenous ketones exert a glucose-lowering effect at least partly mediated via insulin stimulation. |
| Myette-Cote 2019 · Am J Clin Nutr | RCT | supports | high | Ketone monoester before oral glucose reduced glycemic response in obesity |
| Ding X et al 2026 · study_type: observational | observational | supports | low | Narrative review of β-hydroxybutyrate in T2DM models; states regulating β-HB via endogenous and exogenous ketogenesis approaches can influence fasting blood glucose, insulin resistance, and body weight in T2DM patients. |
| Vestergaard 2021 · Diabetes Obes Metab | RCT | supports | high | Ketone ester suppressed appetite and lowered glucose vs isocaloric glucose in healthy men |
| Falkenhain K, Daraei A, Forbes SC, Little JP] # full byline read at reread 2026-08-25 2022 · Adv Nutr | meta-analysis | supports | high | Between-condition pool of 33 comparisons (NOT the review's 43 trials / 586 participants): average blood glucose across the post-supplementation period MD = -0.47 mM (95% CI -0.57, -0.36; P < 0.001), I2 = 0.0%, Egger P = 0.93, prediction interval -0.90 to -0.04 mM - the one analysis the authors exempt from their heterogeneity caveat. Monoesters -0.61 mM vs salts -0.24 mM (P < 0.001). The pool spans fasted and fed states and no postprandial-specific pooled MD is reported; postprandial comparisons are a minority (3 OGTT, 1 mixed-meal, plus 7 non-fasted within-group), though outcome-type subgroups did not differ significantly. Population is 51 of 58 comparisons at healthy weight, only 2 prediabetes and 1 T2D; 36 randomized and 22 non-randomized comparisons pooled together. |
| Charles 2024 · Biomolecules | RCT | supports | moderate | Ketone ester reduced plasma glucose during acute nutritional ketosis (crossover RCT) |
| Bangshaab M et al] # corrected 2026-08-17 from PubMed; was [(T2D crossover) 2026 · (RCT) | RCT | supports | moderate | T2D crossover: dose-dependent reduction in postprandial glucose, lipids, ghrelin |
| Graybeal AJ et al 2025 · Physiol Rep | RCT | supports | moderate | [FT-verified, PMC12661118] Randomised single-blind placebo-controlled matched-pairs CROSSOVER (order randomised via random.org, >=4 d washout, no order effects all p >= 0.075), prospectively registered NCT05651243. Exposure: 282 mg/kg body mass ketone monoester (DeltaG Tactical, TdeltaS Global) in 250 mL water versus a volume- and taste-matched Bitrex/stevia/cellulose placebo, so the claim's own exposure IS the randomised variable and RCT is the right grade. DENOMINATOR CORRECTED at reread 2026-08-25: n = 16 is not the enrolled cohort - 10 per group were recruited and 'two participants from each group ... had incomplete respiratory gas data across multiple timepoints due to device malfunction. Thus, these participants were excluded from this evaluation', leaving 8 MetS (5 M, 3 F) and 8 age/race/ethnicity-matched non-MetS. FEEDING STATE, which the previous extract did not name: participants 'arrived at the laboratory following an >=8 h overnight fast' and ingested nothing but the study drink - no meal, no OGTT, no mixed-meal test - so this is post-INGESTION glucose in the fasted state, not post-meal glucose. Held ON this claim because sibling rows and the ketone-bhb-ma-2022 pool likewise span fasted and fed states; the object mismatch is flagged as a claim-level question rather than settled inside one row. ON THIS CLAIM: condition x time interaction for blood glucose p = 0.003 (eta2p = 0.34), where 'blood glucose decreased from 45 to 105 min post KE in the combined (Figure 2d; all p < 0.001), MetS (Figure 2c; all p < 0.001) and non-MetS groups (Figure 2c; all p < 0.007)', while 'No differences from baseline blood glucose were observed during the placebo trial for any group (all p >= 0.292)'; the MetS-versus-control contrast was null, i.e. reductions comparable between groups. NO MAGNITUDE IS AVAILABLE: not one glucose concentration, delta or effect size appears anywhere in the text - the values exist only in Figure 2c,d - so this row votes a direction with no number behind it, on a claim whose own scope asserts ~0.5 mM. Measured in duplicate by point-of-care meter (Keto-Mojo GK+), not a lab assay, at three timepoints only (baseline, 45, 105 min). Quality held at moderate: registered, placebo-controlled, taste-matched, baseline glucose not different between trials (all p >= 0.075), 83.7% power for the interaction - against n = 16, 'investigators were not blinded to treatment conditions', treatments not energy-matched (KE averaged 125 kcal in MetS and 90.8 kcal in non-MetS versus a near-zero placebo), no insulin or free fatty acids measured, and a figure-only endpoint. DUPLICATE-POPULATION RISK, flagged not applied: this is an explicit secondary analysis and 'Only a limited set of secondary variables, including descriptive characteristics and capillary concentrations of beta-hydroxybutyrate (BHB) and blood glucose, are shared across related investigations (Graybeal et al., 2025; Stavres et al., 2025)' - the two variables this source votes on are precisely the shared ones. Neither parent is in the vault today, so the row is not zeroed; if Graybeal 2025 or Stavres 2025 (both NCT05651243) is ever ingested, this row must become duplicate-population. Funded by NIGMS U54GM115428; the authors declare no conflicts of interest. |
| Marcotte-Chenard 2025 · Am Nutr Assoc | RCT | mixed | moderate | Free-living BHB in T2D feasible; glucose-lowering signal present but pilot, underpowered |
| Yu 2023 · Complement Ther Clin Pract | meta-analysis | supports | high | 3-level meta-analysis: ketone supplements significantly lower blood glucose and insulin vs control |
| Stubbs 2018 · Obesity | RCT | supports | low | Ketone ester lowered blood glucose alongside ghrelin/appetite suppression in healthy humans |
| Li S et al 2026 · study_type: animal | animal | supports | moderate | STZ-induced T1D mice given 7-week oral 3HB (exogenous ketone) showed improved glucose metabolism and reduced hepatic/intestinal glucose uptake via GPR109A-mediated suppression of glucose transporters; confirmed in vitro in hepatocytes/IEC-6 |
| Bolyard 2023 · Nutrients | RCT | tested-null | moderate | KME and KME/salt raised R-BHB with inverse R-BHB-glucose correlation at 30 min vs placebo |
| Dörner R et al 2024 · study_type: RCT | RCT | contradicts | high | n=8 healthy adults, crossover WRIC study; isocaloric diet + ketone salts (38.7g BHB/day, EXO arm) vs control: no differences in basal or postprandial glucose/insulin levels or insulin sensitivity vs isocaloric control; explicitly 'no effect |
| Walsh 2020 · Front Physiol | RCT | supports | moderate | KME before OGTT attenuated hyperglycemia in normal-weight and obese adults |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.